These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11702369)

  • 1. Bexarotene.
    Lowe MN; Plosker GL
    Am J Clin Dermatol; 2000; 1(4):245-50; discussion 251-2. PubMed ID: 11702369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
    J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene ligand pharmaceuticals.
    Hurst RE
    Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
    Sherman SI
    Clin Lymphoma; 2003 Mar; 3(4):249-52. PubMed ID: 12672276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    Väkevä L; Ranki A; Hahtola S
    Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical and oral bexarotene.
    Schadt CR
    Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
    Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
    Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
    Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
    Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of cutaneous T-cell lymphoma with a novel retinoid.
    Heald P
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S45-9. PubMed ID: 11707864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.